FSR Doubles Investment in Cardiac Sarcoidosis Research with $200,000 in Grants to Advance Diagnostic and Treatment Breakthroughs
27 nov. 2024 13h51 HE
|
Foundation for Sarcoidosis Research
FSR Doubles Investment in Cardiac Sarcoidosis Research with $200,000 in Grants to Advance Diagnostic and Treatment Breakthroughs
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
16 nov. 2024 17h40 HE
|
Foundation for Sarcoidosis Research
FSR secured clarification from the U.S. Department of Labor ensuring FMLA coverage for employees participating in clinical trials.
Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA
31 oct. 2024 15h28 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research (FSR) hosts Externally Led Patient-Focused Drug Development (EL-PFDD) meeting for Sarcoidosis
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
08 oct. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
02 oct. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
Foundation for Sarcoidosis Research Expands Scientific Advisory Board with 14 New Experts to Enhance Sarcoidosis Research and Patient Care
28 août 2024 16h48 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research appoints fourteen new members to serve the organization’s Scientific Advisory Board.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
13 août 2024 16h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
The Foundation for Sarcoidosis Research Awards $300,000 to Support Early-Career Investigators Through the Sarcoidosis Research Fellowship Grant
24 juil. 2024 13h16 HE
|
Foundation for Sarcoidosis Research
CHICAGO, July 24, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is pleased to announce that Dr. Greer Waldrop, University of California, San Francisco, and Dr. Miles...
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
22 juil. 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
03 juin 2024 08h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”